Colorectal Cancers: An Update on Their Molecular Pathology.
Colorectal Cancers: An Update on Their Molecular Pathology.
复制标题
DOI：
10.3390/cancers10010026
复制
发表时间：
2018-01-20
期刊：
影响因子：
5.2
通讯作者：
Inamura K
中科院分区：
文献类型：
--
作者：
Inamura K
结直肠癌（crc）是全球癌症相关死亡的第三大原因。越来越多的证据表明，crc不是一种单一的、统一的疾病类型，而是由一组分子异质性疾病组成，其特征是一系列基因组和表观基因组改变。这种异质性减缓了分子靶向治疗作为一种精准医疗形式的发展。最近关于crc的综合分子特征和分子病理学检查的数据增加了我们对crc基因组和表观基因组景观的理解，这使得crc能够被重新分类为生物学和临床意义的亚型。对CRC分子病理流行病学知识的增加，使其从一个模糊理解的异质组疾病演变为具有不同临床过程的特征分子亚型，这一发展将允许实施个性化治疗和更好地管理CRC患者。这篇综述提供了我们对crc分子和流行病学景观的最新进展的观点，包括高通量分析获得的综合分子特征的结果，以及关于其分子病理学、免疫生物标志物和相关肠道微生物组的最新进展。我们对分子特异性亚型的潜在个性化治疗的理解也进行了回顾。
Colorectal cancers (CRCs) are the third leading cause of cancer-related mortality worldwide. Rather than being a single, uniform disease type, accumulating evidence suggests that CRCs comprise a group of molecularly heterogeneous diseases that are characterized by a range of genomic and epigenomic alterations. This heterogeneity slows the development of molecular-targeted therapy as a form of precision medicine. Recent data regarding comprehensive molecular characterizations and molecular pathological examinations of CRCs have increased our understanding of the genomic and epigenomic landscapes of CRCs, which has enabled CRCs to be reclassified into biologically and clinically meaningful subtypes. The increased knowledge of the molecular pathological epidemiology of CRCs has permitted their evolution from a vaguely understood, heterogeneous group of diseases with variable clinical courses to characteristic molecular subtypes, a development that will allow the implementation of personalized therapies and better management of patients with CRC. This review provides a perspective regarding recent developments in our knowledge of the molecular and epidemiological landscapes of CRCs, including results of comprehensive molecular characterizations obtained from high-throughput analyses and the latest developments regarding their molecular pathologies, immunological biomarkers, and associated gut microbiome. Advances in our understanding of potential personalized therapies for molecularly specific subtypes are also reviewed.
登录
查看更多内容
影响因子：
7
作者：
Castellarin, Mauro;Warren, Rene L.;Holt, Robert A.
通讯作者：
Holt, Robert A.
DOI：
10.1126/science.1224820
发表时间：
2012-10-05
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Arthur JC;Perez-Chanona E;Mühlbauer M;Tomkovich S;Uronis JM;Fan TJ;Campbell BJ;Abujamel T;Dogan B;Rogers AB;Rhodes JM;Stintzi A;Simpson KW;Hansen JJ;Keku TO;Fodor AA;Jobin C
通讯作者：
Jobin C
影响因子：
7.3
作者：
Briggs, Sarah;Tomlinson, Ian
通讯作者：
Tomlinson, Ian
影响因子：
28.2
作者：
Corcoran RB;Ebi H;Turke AB;Coffee EM;Nishino M;Cogdill AP;Brown RD;Della Pelle P;Dias-Santagata D;Hung KE;Flaherty KT;Piris A;Wargo JA;Settleman J;Mino-Kenudson M;Engelman JA
通讯作者：
Engelman JA
影响因子：
82.9
作者：
Dorard, Coralie;de Thonel, Aurelie;Duval, Alex
通讯作者：
Duval, Alex